Amylyx Pharmaceuticals, Inc. AMLX Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s accrued liabilities, current?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported accrued liabilities, current of $11.28M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s accrued liabilities, current changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s accrued liabilities, current decreased by 6.5% year-over-year, from $12.07M to $11.28M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s accrued liabilities, current?
- Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s accrued liabilities, current has grown at a -22.4% compound annual growth rate (CAGR), from $38.31M to $17.91M.